Researchers using genetically diverse Collaborative Cross mice demonstrated that inherited genetic variability significantly influences tumor response to immune checkpoint inhibitors. This advances understanding of why some patients benefit from immunotherapies while others do not, highlighting the role of tumor genetics alongside immune and therapy-related factors. The findings, published in Cell Reports, underscore importance of precision approaches to improve cancer immunotherapy efficacy by accounting for host genetic differences.